Matthew J. Pfeffer was appointed Chief Executive Officer of MannKind, effective January 10, 2016, replacing Alfred Mann who has been serving as interim CEO since November 19, 2015. Mr. Pfeffer will continue to serve as the Chief Financial Officer of MannKind where he held the position since April 2008. He was also appointed to fill an existing vacancy on the board of directors, effective January 10, 2016.
Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer is a member of the board of directors of Second Sight Medical Products in Sylmar, California. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.
Raymond W. Urbanski, MD, PhD is our Chief Medical Officer. Dr. Urbanski has more than 25 years of research, clinical, and pharmaceutical industry experience developing numerous new drugs and indications across oncology, rheumatology, cardiology, endocrinology, and immunology. Prior to joining MannKind, he most recently held the position of Chief Medical Officer at Mylan, Inc. From 2004 to 2011 Dr. Urbanski was with Pfizer, advancing to the positon of Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of R&D and CMO at Suntory Pharmaceuticals. Dr. Urbanski earned both his MD and Ph.D. in Pharmacology and Toxicology, at the University of Medicine and Dentistry of New Jersey - New Jersey Medical School. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia.
Michael Castagna is our Chief Commercial Officer. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb's Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science - Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.
Stuart A. Tross, Ph.D., is our Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Facilities. Dr. Tross joins MannKind with extensive experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and Security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology.
David B. Thomson, Ph.D., J.D. has been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at the Toronto law firm of Davies Ward Phillips & Vineberg LLP. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University in New York. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.
Joseph Kocinsky is our Corporate Vice President of Technical Operations and Chief Technology. Mr. Kocinsky has over 28 years experience in the pharmaceutical industry in technical operations and product development. Prior to joining MannKind in 2003, he held a variety of technical and management positions with increased responsibility at Schering-Plough. Mr. Kocinsky holds a bachelor’s degree in Chemical Engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master's degree in Business Administration from Seton Hall University.
Rose Alinaya became the Senior Vice President, Principal Accounting Officer on January 12, 2016 for MannKind Corporation.
Ms. Alinaya has been our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003 with responsibility for finance, accounting, tax, treasury, investor relations and risk management.
Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.
Stock transaction information provided by EDGAR Online. MannKind Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.